BRIEF published on 08/27/2024 at 13:05, 2 years 2 months ago Pharnext begins liquidation proceedings Creditors Liquidation Paris Commercial Court Pharnext Suspension Of Listing
BRIEF published on 08/27/2024 at 13:05, 2 years 2 months ago Pharnext entame une procédure de liquidation judiciaire Liquidation Judiciaire Tribunal De Commerce De Paris Suspension De Cotation Pharnext Créditeurs
PRESS RELEASE published on 08/27/2024 at 13:00, 2 years 2 months ago Ouverture d'une procédure de liquidation judiciaire Pharnext SCA, société biopharmaceutique en liquidation judiciaire après procédure de conciliation. Suspension de la cotation des actions Biopharmaceutique Liquidation Judiciaire Suspension Cotation Pharnext Procédure Conciliation
BRIEF published on 07/04/2024 at 20:05, 2 years 3 months ago Pharnext announces the termination of the financing contract granted by Néovacs Investors Termination Funding Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years 3 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Financement Investisseurs Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years 3 months ago Pharnext annonce la résiliation du contrat de financement accordé par Néovacs Pharnext annonce la résiliation anticipée du contrat de financement avec Néovacs suite à des cas de défaut. La société sollicite Global Tech Opportunities 13 pour son soutien Financement Pharnext Résiliation Néovacs Global Tech Opportunities
BRIEF published on 06/18/2024 at 18:35, 2 years 4 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext Procédure De Conciliation CMT1A PXT3003 Tasly
BRIEF published on 06/18/2024 at 18:35, 2 years 4 months ago Pharnext announces the extension of the conciliation procedure until July 15, 2024 Pharnext Conciliation Procedure CMT1A PXT3003 Tasly
PRESS RELEASE published on 06/18/2024 at 18:30, 2 years 4 months ago Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 juillet 2024 pour poursuivre l'étude clinique de Phase III de PXT3003. Les résultats seront communiqués prochainement Conciliation Étude Clinique Pharnext PXT3003 Maladie Neurodégénérative
BRIEF published on 05/07/2024 at 19:15, 2 years 5 months ago Adjustment of the nominal value at Pharnext Biopharmaceutical Capital Reduction Pharnext Nominal Value Neurodegenerative Diseases
Published on 10/28/2026 at 02:55, 5 hours 3 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 5 hours 8 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 8 hours 18 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 8 hours 33 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/27/2026 at 21:30, 10 hours 28 minutes ago Apex Announces Closing of Over-Allotment Option
Published on 10/28/2026 at 07:42, 16 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual General Meeting results
Published on 10/28/2026 at 07:32, 25 minutes ago Correction: PALFINGER sharpens portfolio and risk profile, strengthening focus, profitability and resilience in the third quarter 2026
Published on 10/28/2026 at 07:30, 28 minutes ago Media Release: Sensirion announces global availability of the single-use SFM3304-D for proximal flow measurement in mechanical ventilation
Published on 10/28/2026 at 07:30, 28 minutes ago Delivery Hero hits one billion orders in Q3 as growth accelerates further, raises full-year guidance
Published on 10/28/2026 at 07:30, 28 minutes ago Symrise delivered strong volume-driven organic sales growth in Q3 2026 and reaffirms full-year outlook
Published on 10/27/2026 at 18:00, 13 hours 58 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 13 hours 58 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
